SEARCH

SEARCH BY CITATION

References

  • 1
    Chue P, Eerdekens M, Augustyns I et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-7.
  • 2
    Bai YM, Ting Chen T, Chen JY et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007;68:18-25.
  • 3
    Keks NA, Ingham M, Khan A et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 2007;191:131-9.
  • 4
    Macfadden W, Ma Y, Haskins JT et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry 2010;7:23-31.
  • 5
    Rosenheck RA, Krystal JH, Lew R et al. Risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011;364:842-51.
  • 6
    Schooler NR, Buckley PF, Mintz J et al. PROACTIVE: Initial results of an RCT comparing long-acting injectable risperidone to 2nd generation oral antipsychotics. Presented at the 50th Annual Meeting of the American College of Neuropsychopharmacology, Kona, December 2011.
  • 7
    Gaebel W, Schreiner A, Bergmans P et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs. quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010;35:2367-77.
  • 8
    Kishimoto T, Robenzadeh A, Leucht C et al. Long-acting injectable vs. oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (in press).
  • 9
    Fusar-Poli P, Kempton M, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 2013;28:57-66.
  • 10
    Tiihonen J, Haukka J, Taylor M et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9.
  • 11
    Kishimoto T, Nitta M, Borenstein M et al. Long acting injectable vs. oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. Presented at the 51st Annual Meeting of the American College of Neuropsychopharamacology, Hollywood, December 2012.
  • 12
    Barnett PG, Scott JY, Rosenheck RA. How do clinical trial participants compare to other patients with schizophrenia? Schizophr Res 2011;130:34-9.
  • 13
    Hoblyn J, Rosenheck RA, Leatherman S et al. Veteran subjects willingness to participate in schizophrenia clinical trials. Psychiatr Q 2013;84:209-18.
  • 14
    Leatherman S, Liang MH, Krystal JH et al. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. Submitted for publication.
  • 15
    Taylor DM, Young CL, Mace S et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004;65:1076-83.
  • 16
    Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull 2007;33:1379-87.
  • 17
    Simpson GM, Mahmoud RA, Lasser RA et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006;67:1194-203.
  • 18
    Fleischhacker WW, Eerdekens M, Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7.
  • 19
    Mohamed S, Rosenheck RA, Harpaz-Rotem I et al. Duration of prescription of long-acting risperidone. Psychiatr Q 2009;80:241-9.